Cb 839

Manufactured by Focus Biomolecules

Sourced in United States

CB-839 is a small molecule inhibitor developed by Focus Biomolecules. It selectively targets glutaminase, an enzyme involved in cellular metabolism. CB-839 can be used as a research tool to study the role of glutaminase in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

4 protocols using cb 839

Reagents for Macrophage Metabolism Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

RPMI-1640 with Glutamax, non-essential amino acids (NEAA), sodium pyruvate, and penicillin–streptomycin (P/S) were from Gibco (Paisley, Scotland, UK). Fetal bovine serum (FBS) was purchased from Life Science Production (Barnet, UK). Cytokines M-CSF, IL-4, and IFN-γ were purchased from Biolegend (San Diego, CA, USA). 2-Deoxy-D-glucose (2-DG), Oligomycin (Oligo), Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP), Rotenone (R/Rot,), and Antimycin A (AA) were purchased from Abcam (Cambridge, UK). Perhexiline (PerHx) and H531 (Hx) were purchased from Tocris (Bristol, UK). CB-839 was purchased from FOCUS Biomolecules (Plymouth Meeting, PA, USA). Trimetazidine (TMZ) was purchased from Sigma-Aldrich (St. Louis, MO, USA). VLX-600 (VLX) was purchased from Cayman Chemical (Ann Arbor, MI, USA). Lipopolysaccharide (LPS) from E. Coli was obtained from Sigma-Aldrich. Any other material used was of analytical grade.

Oyarce C., Vizcaino-Castro A., Chen S., Boerma A, & Daemen T. (2021). Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic drugs. Oncoimmunology, 10(1), 1898753.

+ Open protocol

+ Expand

Metabolic Modulation in Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following drugs were used: 6‐Diazo‐5‐oxo‐l‐norleucine (Don, D2141, Sigma‐Aldrich); Sodium dichloroacetate (DCA, 347795, Sigma‐Aldrich); NCT‐502 and PHGDH inactive (19716 and 19717, Cayman); Doxycycline (Dox, D9891, Sigma‐Aldrich), Oligomycin (sc‐203342, Santa Cruz Biotechnology); FCCP (sc‐203578, Santa Cruz Biotechnology); Antimycin (sc‐202467, Santa Cruz Biotechnology); Rotenone (sc‐203242, Santa Cruz Biotechnology); Cyt.C (C2037, Sigma‐Aldrich) CB‐839 (10‐4556, Focus Biomolecules); Adenosine diphosphate (ADP, A2754, Sigma‐Aldrich).

Xu R., Jones W., Wilcz‐Villega E., Costa A.S., Rajeeve V., Bentham R.B., Bryson K., Nagano A., Yaman B., Olendo Barasa S., Wang Y., Chelala C., Cutillas P., Szabadkai G., Frezza C, & Bianchi K. (2020). The breast cancer oncogene IKKε coordinates mitochondrial function and serine metabolism. EMBO Reports, 21(9), e48260.

+ Open protocol

+ Expand

Metabolic Profiling of Cell Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols

We used the following specific chemical compounds for cell treatment: (aminooxy)acetic acid hemihydrochloride (Sigma-Aldrich C13408), CB-839 (Focus Biomolecules 10-4556), BPTES (Sigma-Aldrich, SML0601), dmOG (Sigma-Aldrich, 349631), methyl pyruvate (Sigma-Aldrich, 371173), 17-β-estradiol (Sigma-Aldrich, E2758), octyl-R-2HG (Sigma-Aldrich, SML2200). Antibodies used in the study were following: Gls1 (Abcam ab156876), PHGDH (Abcam ab57030), anti-FLAG (M2, Sigma-Aldrich F1804), IDH2 (Abnova H00003418-M01), ATP5A (Abcam ab14748), Tim23 (Abcam ab176558), PDH (Abcam ab92696), and β-actin (Abcam ab8226).

Špačková J., Gotvaldová K., Dvořák A., Urbančoková A., Pospíšilová K., Větvička D., Leguina-Ruzzi A., Tesařová P., Vítek L., Ježek P, & Smolková K. (2021). Biochemical Background in Mitochondria Affects 2HG Production by IDH2 and ADHFE1 in Breast Carcinoma. Cancers, 13(7), 1709.

+ Open protocol

+ Expand

Cytotoxicity Assay for Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Compounds were added 24 hours after cell plating and viability was assessed at the specified time point using the CellTiter-Glo luminescent cell viability assay (Promega) according to the manufacturer’s instructions. Data were normalized to vehicle-treated controls and IC₅₀ curves were generated using Graphpad Prism. Viability assays were generally performed at least twice. In assays that included N-acetylcysteine (Sigma-Aldrich) treatment, the medium was replaced every 48 hours except in RNAi experiments where additional N-acetylcysteine was added every 48 hours. CB-839 was obtained from Focus Biomolecules (14 (link)). Erastin was purchased from Cayman Chemical (15 (link)), and BPTES was acquired from Sigma (16 (link)).

Beatty A., Fink L.S., Singh T., Strigun A., Peter E., Ferrer C.M., Nicolas E., Cai K.Q., Moran T.P., Reginato M.J., Rennefahrt U, & Peterson J.R. (2017). Metabolite profiling reveals the glutathione biosynthetic pathway as a therapeutic target in triple negative breast cancer. Molecular cancer therapeutics, 17(1), 264-275.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!